BPC-157 & TB-500 Blend by Meditech is a pharmaceutical-grade combination lyophilized peptide formulation containing Body Protection Compound-157 (BPC-157) at 2 mg and Thymosin Beta-4 (TB-500) at 2 mg per vial, supplied as 3 vials of 4 mg blend alongside 3 vials of 2 mL sterile reconstitution water. The combination of these two structurally distinct regenerative peptides in a single formulation represents a research-oriented approach to synergistic tissue repair signaling, documented in peptide pharmacology literature for their complementary and potentially additive effects on soft tissue healing, angiogenesis, and inflammatory modulation.
 
✔ Key Research Insights
Studied for BPC-157's documented role in accelerating tendon, ligament, muscle, and nerve tissue healing in research subjects, with effects on growth factor upregulation and fibroblast activity documented across regenerative peptide research literature
Investigated for TB-500's systemic regenerative profile, with documented effects on actin polymerization regulation, cell migration, and tissue remodeling in comparative peptide pharmacology research
Researched for the combined formulation's influence on angiogenesis — the formation of new blood vessels — with both constituent peptides independently documented for pro-angiogenic activity in preclinical and peptide research observations
Examined for anti-inflammatory and oxidative stress reduction effects at cellular injury sites, documented across BPC-157 and TB-500 research literature both independently and in combination protocols
Documented for BPC-157's investigated neuroprotective and gastrointestinal mucosal repair properties, representing pharmacologically distinct research areas specific to the BPC-157 compound within the blend
Researched for post-surgical and injury recovery acceleration parameters in documented peptide research protocols, with both constituent compounds investigated independently and in combination across regenerative medicine research literature
Manufactured by Meditech to pharmaceutical-grade lyophilized peptide purity and formulation standards
 
📦 Product Specifications
Manufacturer: Meditech
Product: BPC-157 & TB-500 Blend
Components:
BPC-157: 2 mg per vial
TB-500: 2 mg per vial
Total Blend per Vial: 4 mg
Volume: 3 vials × 4 mg blend + 3 vials × 2 mL sterile water
Form: Lyophilized peptide powder requiring reconstitution prior to administration
Administration: Subcutaneous injection; localized or systemic depending on research protocol
Storage: Lyophilized — store at −20°C; Reconstituted — refrigerate at 2–8°C and use within documented stability window
Dosage considerations may vary. Consulting a qualified professional is recommended.
 
⚙ How It Works
The BPC-157 & TB-500 blend delivers two mechanistically distinct regenerative peptides simultaneously, each contributing a complementary pharmacological profile in research subjects. BPC-157 is a synthetic pentadecapeptide derived from a protective protein found in gastric juice, documented in preclinical and peptide research for its local and systemic effects on tissue repair through multiple growth factor pathways including upregulation of vascular endothelial growth factor (VEGF) and fibroblast growth factor (FGF), promoting angiogenesis, fibroblast proliferation, and collagen synthesis at injury sites. BPC-157 has additionally been investigated in research literature for neuroprotective properties and gastrointestinal mucosal repair mechanisms, representing pharmacological research areas distinct from its musculoskeletal healing applications. TB-500 is a synthetic analogue of Thymosin Beta-4, an endogenous 43-amino acid peptide involved in the regulation of actin polymerization — a fundamental process in cell migration, wound healing, and tissue remodeling. In research subjects, TB-500 promotes systemic regenerative signaling by facilitating the migration of endothelial cells and keratinocytes to sites of tissue damage, supporting vascular repair and inflammatory resolution across a broad systemic distribution profile documented in comparative peptide pharmacology research. The combination of BPC-157's localized growth factor upregulation with TB-500's systemic actin-mediated cellular migration activity has been examined in peptide research for potentially complementary and synergistic effects on comprehensive tissue repair cascades. Reconstitution with bacteriostatic water is standard protocol prior to subcutaneous administration in documented research settings.
 
⭐ Product Overview
Manufactured by Meditech to pharmaceutical-grade lyophilized peptide purity and formulation standards
Dual-peptide combination formulation delivering complementary regenerative mechanisms — BPC-157 via localized growth factor pathway activation and TB-500 via systemic actin-mediated cellular repair signaling
Both constituent peptides independently documented in peptide pharmacology research for pro-angiogenic, anti-inflammatory, and soft tissue repair properties, with combination protocols representing an area of active research interest
Supplied with sterile reconstitution water and requiring storage at −20°C in lyophilized form, consistent with standard pharmaceutical peptide preservation protocols
Widely referenced in regenerative medicine and peptide pharmacology research under the BPC-157, Body Protection Compound, Thymosin Beta-4, and TB-500 designations